Table 2.
Baseline Characteristics | |
---|---|
Pre-existing eye disease | 11 (4 documented as mild/inactive) |
Duration of Medical Treatment (months) | 24 (3 weeks to 12 years) |
Technetium uptake (%) | 4.3 (0.8–66) |
TSH receptor antibody (IU/L) | 8 (0–240) |
Smoker (documented) | 15 |
Glucocorticoid cover with pre-existing eye disease | 7 |
Data are expressed as median (range)